The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective

Heart

Volumn 100, Issue 13, 2014, Pages 1031-1036

  Griffiths, A ^a   Paracha, N ^a   Davies, A ^a   Branscombe, N ^b   Cowie, Martin R ^c   Sculpher, M ^a,d  

^a ICON PLC   (United Kingdom)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE;

AGED; ARTICLE; COHORT ANALYSIS; DEATH; DRUG COST; DRUG INDICATION; DRUG LABELING; DRUG USE; ECONOMIC EVALUATION; EUROPEAN UNION; HEALTH CARE COST; HEART FAILURE; HEART RATE; HIDDEN MARKOV MODEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HEART FAILURE; HEART RATE; HOSPITAL COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902381712     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304598     Document Type: Article

References (22)

1. British Heart Foundation. Coronary heart disease statistics. BHF, 2012. http://www.heartstats.org
2. British Heart Foundation. Heart health conditions: heart failure. BHF, 2013. http://www.bhf.org.uk
3. NICE. Chronic Heart Failure- National clinical guideline for diagnosis and management in primary and secondary care. 2010.
4. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1:H64-9. (Pubitemid 29304286)
5. Black J. Drugs from emasculated hormones: the priniciples of syntopic antagonism. Bio Rep 1989;9:253-72. (Pubitemid 19189384)
6. Swedberg K, Komajda M, Böhm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIfT study. J Am Coll Cardiol 2012;59:1938-45.
7. Böhm M, Borer J, Ford I, et al. Heart rate at baseline in fluences the effect of ivabradine on cardiovascular outcomes in chronic heart failure. Analysis from the SHIfT study. Clin Res Cardiol 2012;10:1-12.
8. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Eur Soc Cardiol 2003;24:464-74. (Pubitemid 36286188)
9. National Institute of Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: National Institute of Health Care Excellence, 2013.
10. Office of National Statistics. Period expectation of life. Office of National Statistics, 2010. http://www.statistics.gov.uk
11. New York Heart Association. New York Heart Association (NYHA) functional classification: the criteria committee of the New York heart association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston, Mass: Little, Brown & Co, 1994. Report No.: 9th ed.
12. Euroqol group. EQ-5D. EuroQol Group, 2011. http://www.euroqol.org/eq-5d/ reference-search/reference-search.html
13. Twisk J. Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge University Press, 2003.
14. The Department of Health. NHS schedule of reference costs 2010/2011. The Department of Health, 2011. http://www.dh.gov.uk
15. Office of National Statistics. Consumer price index. Office of National Statistics, 2011. http://www.statistics.gov.uk/hub/index.html
16. Cleland J. CARE-HF long term follow up [abstract]. Eur Soc Cardiol 2011.
17. Teng K, Hung J, Knuiman M, et al. Trends in long-term cardiovascular mortality and morbidity in men and women with heart failure of ischaemic versus non-ischaemic aetiology in Western Australia betweeen 1990 and 2005. Int J Cardiol 2011;158:405-10.
18. The Information Centre for health and social care. Hospital episode statistics online. National Health Service, 2012. http://www.hesonline.nhs.co.uk
19. National Institute for Cardiovascular Outcomes Research (NICOR). National Heart Failure Audit. 2011.
20. Golher A, Geisler B, Manne J, et al. Utility estimates for decision-analytic modeling in chronic heart failure - health states based on the NYHA classes and number of rehospitalisations. Value Health 2009;12:185-7.
21. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.
22. National Institute of Health and Care Excellence. Ivabradine for treating chronic heart failure: costing template. NICE technology appraisal 267, 2012. http://guidance.nice.org.uk/TA267/CostingTemplate/xls/English